All In Biotech

Drug Trial Radar · NCT07063875

Adding IL-2 to Tebentafusp to Eradicate Cancer Progression

Supplementing With IL-2 to Verifiably eRadicate Radiological Progression

Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

8

Planned (sponsor's estimate)

Start

Jun 1, 2025

Primary completion

Sep 1, 2027

Study completion Sep 1, 2028

Sponsor

Lead sponsor
St Vincent's Hospital, SydneyAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jul 14, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A recent clinical trial found that after 36 months, patients taking tebentafusp had a median survival of 21.6 months, compared to 16.9 months for those in the control group. Since recruitment for tebentafusp in metastatic uveal melanoma (mUM) has ended, a new trial is starting to test whether adding IL-2 can help overcome resistance to tebentafusp and improve its effectiveness. This study aims to answer: 1. Can combining tebentafusp with IL-2 improve tumor response and overall survival? 2. What are the benefits and side effects of this combination therapy? All participants will receive both IL-2 and tebentafusp in a 28-day treatment cycle. The dosing schedule is as follows: Cycle1: Day1-3 IL-2 Day4 Tebentafusp Day 10 IL-2 Day 11 Tebentafusp Day 17 IL-2 Day 18 Tebentafusp Day 24 IL-2 Day 25 Tebentafusp Cycle 2 \& thereafter Day 1 IL-2 Day 2 Tebentafusp Day 8 IL-2 Day 9 Tebentafusp Day 15 IL-2 Day 16 Tebentafusp Day 22 IL-2 Day 23 Tebentafusp

Conditions

  • Uveal Melanoma
  • Metastatic Uveal Melanoma
  • Metastatic Uveal Melanoma in the Liver

Interventions

  • AldesleukinDrug

    IL-2 in combination with Tebentafusp

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety of Combination therapyTime frame: Through study completion, approx 1 year

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Kinghorn Cancer Centre, St. Vincent's Hospital

    Sydney, New South Wales, Australia · Recruiting

  • Alfred Hospital

    Melbourne, Victoria, Australia · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.